Akebia Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AKBA | BCRX | KMDA | IRWD | CPHI | HCM | |
|---|---|---|---|---|---|---|
| Market cap | 218.97M | 2.14B | 452.45M | 621.30M | 37.39M | 2.38B |
| P/E (TTM) | — | — | 20.6 | 4.9 | — | 136.8 |
| Forward P/E | -2.2 | 8.9 | 13.6 | 2.5 | — | 52.8 |
| Price/book | 8.6 | -4.7 | 1.7 | -3.8 | 1.0 | 1.9 |
| Dividend yield | — | — | 2.10% | — | — | — |
| 1-year change | −71.68% | +30.22% | +17.44% | +158.11% | −53.48% | −8.38% |
| Today | −1.36% | −2.22% | −2.97% | −1.57% | −0.17% | −2.98% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All AKBA news ›All Transcripts on Akebia Therapeutics, Inc. (AKBA)
Find all the latest transcripts on Akebia Therapeutics, Inc. Transcripts Akebia Therapeutics, Inc. All financial news and data tailored to specific country editions
Akebia Therapeutics, Inc. : Insider Transactions
Follow insider transactions on Akebia Therapeutics, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Akebia Therapeutics, Inc. Latest insider transactions for…
Akebia Therapeutics, Inc.: News in other languages | AKBA | US00972D1054
Akebia Therapeutics, Inc.: News, information and stories for Akebia Therapeutics, Inc. | Nasdaq: AKBA | Nasdaq Other languages Akebia Therapeutics, Inc. All financial news and data tailored to specific country editions
Akebia Therapeutics, Inc.: Latest Headlines - Nasdaq Stock Exchange
Find the latest highlights on Akebia Therapeutics, Inc. at the Nasdaq stock exchange. Highlights Akebia Therapeutics, Inc. All financial news and data tailored to specific country editions
Akebia Therapeutics, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Akebia Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time AKBA price, Nasdaq stock exchange Relative Strength Chart Akebia Therapeutics, Inc. All financial news and data tailored to specific…
Akebia Therapeutics Strengthens Vafseo® Patent Portfolio
Published on 06/10/2026 at 08:00 am EDT Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. Known hypersensitivity to VAFSEO or any of its components and uncontrolled hypertension are…
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial
Akebia Therapeutics said Monday it has dosed the first patient in an open-label Phase 2 basket trial testing ebribafusp as a treatment for rare complement-mediated kidney diseases. The mid-stage... Akebia Therapeutics Doses First Patient…
Transcript : Akebia Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to Akebia's First Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised Transcript : Akebia Therapeutics, Inc., Q1…
Akebia Therapeutics Announces First Participants Dosed In Phase 1 Clinical Trial Of AKB-9090
Akebia Therapeutics, Inc. announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase inhibitor being... announced the first participants…
Akebia Therapeutics Initiates Phase 2 Basket Trial to Study Ebribafusp in Rare Kidney Diseases
Akebia Therapeutics announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney... Akebia Therapeutics announced the…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com10
-
manilatimes.net1
-
marketbeat.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.